STOCK TITAN

Pieris Pharmaceu - PIRS STOCK NEWS

Welcome to our dedicated page for Pieris Pharmaceu news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceu stock.

Pieris Pharmaceuticals, Inc. (PIRS) delivers innovative biopharmaceutical solutions through its proprietary anticalin protein platform. This dedicated news hub provides investors and industry stakeholders with essential updates on clinical developments, strategic collaborations, and therapeutic advancements.

Track critical updates including clinical trial progress in immuno-oncology and respiratory therapies, partnership announcements with global pharmaceutical leaders, and regulatory milestones for novel anticalin-based treatments. Our curated news collection serves as a centralized resource for understanding PIRS's role in advancing precision-targeted therapeutics.

Discover timely updates on pipeline developments across key therapeutic areas and business strategy implementations. This repository is designed to help users monitor the company's progress in translating innovative protein engineering into clinical-stage assets.

Bookmark this page for streamlined access to Pieris Pharmaceuticals' latest announcements and scientific breakthroughs. Regularly updated to ensure you stay informed about this clinical-stage biotech innovator's evolving landscape.

Rhea-AI Summary

Palvella Therapeutics and Pieris Pharmaceuticals have announced a definitive merger agreement to create a Nasdaq-listed, clinical-stage biopharmaceutical company. The combined entity will focus on developing novel treatments for rare genetic skin diseases, particularly QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (LMs) and cutaneous venous malformations.

Key points:

  • Expected $80.5 million in cash at closing, including $78.9 million from private financing
  • Cash runway into second half of 2027
  • Funding through multiple clinical trial milestones
  • QTORIN™ rapamycin has FDA Breakthrough Therapy and Fast Track Designations
  • Merger expected to close in Q4 2024, subject to approvals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
88.6%
Tags
-
Rhea-AI Summary
Pieris Pharmaceuticals announced a 1-for-80 reverse stock split to comply with Nasdaq's minimum bid price requirement, reducing outstanding shares to 1.2 million from 98.9 million, effective April 23, 2024. The split aims to maintain listing on the Nasdaq Capital Market under the symbol PIRS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
-
Rhea-AI Summary
Pieris Pharmaceuticals (PIRS) announced a strategic update to maximize potential milestones from its immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier. The company aims to extend its cash runway into 2027 through cost-saving measures. Despite unsuccessful negotiations for a strategic merger, Pieris plans to focus on stockholder value by maintaining a lean business model and pursuing milestone and royalty monetization agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
none
Rhea-AI Summary
Pieris Pharmaceuticals achieves milestone payment from Boston Pharmaceuticals for dosing first patient in phase 1/2 study of BOS-342, a biotherapeutic for respiratory diseases and cancer. Pieris could receive up to $350 million in milestone payments and royalties on sales of BOS-342.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
-
Rhea-AI Summary
Pieris Pharmaceuticals provides a strategic update following recent events that impacted its respiratory franchise. AstraZeneca discontinues enrollment in Phase 2a study for elarekibep and terminates R&D collaboration agreement. Pieris focuses on new partnerships, capital preservation, and cost-saving measures. The company retains Stifel, Nicolaus & Company as its exclusive financial advisor for strategic options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
Rhea-AI Summary
Pieris Pharmaceuticals announced that AstraZeneca has decided to discontinue and cease dosing in the clinical studies of elarekibep, an inhaled asthma treatment. This decision was based on lung findings from a non-clinical toxicology study. Pieris will review the implications of the data and AstraZeneca's decision before providing an update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Pieris Pharmaceu

Nasdaq:PIRS

PIRS Rankings

PIRS Stock Data

17.96M
1.30M
0.07%
52.92%
1.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON